PPD Appoints Vice-President of Central Laboratory Development

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-05-04-2016
Volume 11
Issue 5

Hacene Mekerri will serve as vice-president of PPD’s central laboratory organization.

Pharmaceutical Product Development, LLC (PPD) announced on April 13, 2016 that Hacene Mekerri has joined the global contract research organization (CRO) to serve as vice-president of its central laboratory organization.

PPD’s service offerings span clinical development, with Phase I–IV services integrated, and comprehensive lab services such as bioanalytical, vaccine sciences, GMP, central lab testing, and biomarkers. PPD’s central laboratory operations are supported by a set of data solutions in Preclarus, PPD’s clinical data platform. This capability enables study sites to access clean central lab data in real-time, improve inventory management and order tracking, facilitate patient management and safety, and establish complete chain of custody for samples.

Mekerri has more than 15 years of management experience in the drug-development industry, including with laboratory companies, CROs, and pharmaceutical companies. More recently, he served as managing director for the Asia Pacific region of a large CRO, as well as global director of data management and country head for a global central laboratory focused on late-stage clinical trials.

Source: PPD

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content